# Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19

> **NCT04803227** · PHASE1 · TERMINATED · sponsor: **Histogen** · enrollment: 13 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Emricasan
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04803227
- **Lead sponsor:** Histogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-11
- **Primary completion:** 2021-05-28
- **Final completion:** 2021-05-28
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Unforeseeable difficulties in recruiting patients. There were no reported serious adverse events.
- **Last updated:** 2022-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04803227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04803227, "Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04803227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*